{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T09:13:11Z","timestamp":1777367591418,"version":"3.51.4"},"reference-count":35,"publisher":"Becaris Publishing Limited","issue":"1","funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Describe demographics, clinical characteristics, healthcare resource utilization (HCRU) and costs in people with multiple sclerosis (pwMS) switching to alemtuzumab from other disease-modifying therapies (DMTs).\n            <jats:bold>Patients &amp; methods:<\/jats:bold>\n            Retrospective, observational study of IBM\n            <jats:sup>\u00ae<\/jats:sup>\n            MarketScan\n            <jats:sup>\u00ae<\/jats:sup>\n            claims database. PwMS previously treated with DMTs and initiating alemtuzumab (1\u00a0January 2013 to 31\u00a0December\u00a02019) were identified. \u201cIndex\u201d was date of alemtuzumab initiation (prescription filled).\n            <jats:bold>Results:<\/jats:bold>\n            The study cohort (n\u00a0=\u00a0341) was primarily female (72%) with (mean\u00a0\u00b1\u00a0standard deviation) age 45.1\u00a0\u00b1\u00a09.5\u00a0years. At index, duration of MS was 5.3\u00a0\u00b1\u00a02.8\u00a0years. HCRU (inpatient\/outpatient services), outpatient costs (including MS-specific MRI\u00a0and emergency room visits)\u00a0and annualized relapse rate significantly reduced over the 2 years following initiation of alemtuzumab. DMT costs reduced over the same period.\n            <jats:bold>Conclusion:<\/jats:bold>\n            Health economic and clinical benefits were seen following switching to alemtuzumab from other DMTs for treatment of MS, in this cohort from the\u00a0USA.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0127","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T10:30:07Z","timestamp":1669631407000},"source":"Crossref","is-referenced-by-count":3,"title":["Health economic outcomes of switching to alemtuzumab from other disease-modifying therapies in people with\u00a0multiple sclerosis in the USA"],"prefix":"10.57264","volume":"12","author":[{"given":"Lita","family":"Araujo","sequence":"first","affiliation":[{"name":"Sanofi, Cambridge, MA\u00a002141, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikanth","family":"Kyatham","sequence":"additional","affiliation":[{"name":"Axtria Inc., Berkeley Heights, NJ\u00a007922, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen G","family":"Bzdek","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA\u00a002141, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Higuchi","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA\u00a002141, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nupur","family":"Greene","sequence":"additional","affiliation":[{"name":"Sanofi, Cambridge, MA\u00a002141, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"24","key":"e_1_3_5_3_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.0000000000009636","article-title":"The 2013 clinical course descriptors for multiple sclerosis: a clarification","volume":"94","author":"Lublin FD","year":"2020","unstructured":"Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ. The 2013 clinical course descriptors for multiple sclerosis: a clarification. Neurology 94(24), 1088\u20131092 (2020).","journal-title":"Neurology"},{"issue":"3","key":"e_1_3_5_4_2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions","volume":"83","author":"Lublin FD","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA Defining the clinical course of multiple sclerosis: The 2013 revisions. Neurology 83(3), 278\u2013286 (2014).","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_5_5_2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson AJ","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 17(2), 162\u2013173 (2018).","journal-title":"Lancet Neurol."},{"issue":"9","key":"e_1_3_5_6_2","first-page":"a028928","article-title":"Clinical Course of Multiple Sclerosis. Cold Spring Harb","volume":"8","author":"Klineova S","year":"2018","unstructured":"Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harb. Perspect. Med. 8(9), a028928 (2018).","journal-title":"Perspect. Med."},{"issue":"14","key":"e_1_3_5_7_2","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton C","year":"2020","unstructured":"Walton C, King R, Rechtman L Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult. Scler. 26(14), 1816\u20131821 (2020).","journal-title":"Mult. Scler."},{"key":"e_1_3_5_8_2","unstructured":"Multiple Sclerosis International Federation. Atlas of MS (3rd Edition): mapping multiple sclerosis around the world key epidemiology findings (2021). www.msif.org\/wp-content\/uploads\/2020\/10\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf"},{"issue":"10","key":"e_1_3_5_9_2","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1212\/WNL.0000000000007035","article-title":"The prevalence of MS in the United States: a population-based estimate using health claims data","volume":"92","author":"Wallin MT","year":"2019","unstructured":"Wallin MT, Culpepper WJ, Campbell JD ; Us Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 92(10), e1029\u2013e1040 (2019).","journal-title":"Neurology"},{"issue":"8","key":"e_1_3_5_10_2","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1212\/WNL.0000000000012323","article-title":"Secondary Progressive Multiple Sclerosis: New Insights","volume":"97","author":"Cree BaC","year":"2021","unstructured":"Cree BaC, Arnold DL, Chataway J Secondary Progressive Multiple Sclerosis: New Insights. Neurology 97(8), 378\u2013388 (2021).","journal-title":"Neurology"},{"issue":"1","key":"e_1_3_5_11_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112","author":"Weinshenker BG","year":"1989","unstructured":"Weinshenker BG, Bass B, Rice GP The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112(Pt 1), 133\u2013146 (1989).","journal-title":"Brain"},{"issue":"6","key":"e_1_3_5_12_2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jamaneurol.2019.0330","article-title":"Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden","volume":"76","author":"Beiki O","year":"2019","unstructured":"Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J. Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a nationwide population-based cohort study in Sweden. JAMA Neurol. 76(6), 665\u2013671 (2019).","journal-title":"JAMA Neurol."},{"issue":"17","key":"e_1_3_5_13_2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1212\/WNL.0b013e3182535cf6","article-title":"Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN\u03b2-1b trial","volume":"78","author":"Goodin DS","year":"2012","unstructured":"Goodin DS, Reder AT, Ebers GC Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN\u03b2-1b trial. Neurology 78(17), 1315\u20131322 (2012).","journal-title":"Neurology"},{"issue":"4","key":"e_1_3_5_14_2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s13311-017-0548-5","article-title":"Therapeutic targets for multiple sclerosis: current treatment goals and future directions","volume":"14","author":"Smith AL","year":"2017","unstructured":"Smith AL, Cohen JA, Hua LH. Therapeutic targets for multiple sclerosis: current treatment goals and future directions. Neurotherapeutics 14(4), 952\u2013960 (2017).","journal-title":"Neurotherapeutics"},{"issue":"2","key":"e_1_3_5_15_2","doi-asserted-by":"crossref","first-page":"e88472","DOI":"10.1371\/journal.pone.0088472","article-title":"Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study","volume":"9","author":"Bergvall N","year":"2014","unstructured":"Bergvall N, Makin C, Lahoz R Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study. PLOS ONE 9(2), e88472 (2014).","journal-title":"PLOS ONE"},{"issue":"10","key":"e_1_3_5_16_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3111\/13696998.2014.940422","article-title":"Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis","volume":"17","author":"Bergvall N","year":"2014","unstructured":"Bergvall N, Petrilla AA, Karkare SU Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. J. Med. Econ. 17(10), 696\u2013707 (2014).","journal-title":"J. Med. Econ."},{"issue":"11","key":"e_1_3_5_17_2","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.4103\/1673-5374.239432","article-title":"Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches","volume":"13","author":"Grand'maison F","year":"2018","unstructured":"Grand'maison F, Yeung M, Morrow SA Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches. Neural. Regen. Res. 13(11), 1871\u20131874 (2018).","journal-title":"Neural. Regen. Res."},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","first-page":"175628642095411","DOI":"10.1177\/1756286420954119","article-title":"The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective","volume":"13","author":"Alroughani R","year":"2020","unstructured":"Alroughani R, Van Wijmeersch B, Al Khaboori J The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective. Ther. Adv. Neurol. Disord. 13, 1756286420954119 (2020).","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"9856","key":"e_1_3_5_19_2","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen JA","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856), 1819\u20131828 (2012).","journal-title":"Lancet"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","first-page":"175628642098213","DOI":"10.1177\/1756286420982134","article-title":"Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial","volume":"14","author":"Coles AJ","year":"2021","unstructured":"Coles AJ, Arnold DL, Bass AD Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. Ther. Adv. Neurol. Disord. 14, 1756286420982134 (2021).","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"e_1_3_5_21_2","unstructured":"Sanofi. LEMTRADA \u00ae (alemtuzumab) injection for intravenous use [prescribing information] (2022). https:\/\/products.sanofi.us\/lemtrada\/lemtrada.pdf"},{"issue":"17","key":"e_1_3_5_22_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant A","year":"2018","unstructured":"Rae-Grant A, Day GS, Marrie RA Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(17), 777\u2013788 (2018).","journal-title":"Neurology"},{"issue":"5","key":"e_1_3_5_23_2","doi-asserted-by":"crossref","first-page":"e0231846","DOI":"10.1371\/journal.pone.0231846","article-title":"Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data","volume":"15","author":"Ohlmeier C","year":"2020","unstructured":"Ohlmeier C, Gothe H, Haas J Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: real world evidence based on German claims data. PLOS One 15(5), e0231846 (2020).","journal-title":"PLOS One"},{"key":"e_1_3_5_24_2","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1472-6963-13-131","article-title":"Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity","volume":"13","author":"Raimundo K","year":"2013","unstructured":"Raimundo K, Tian H, Zhou H Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity. BMC Health Serv. Res. 13, 131 (2013).","journal-title":"BMC Health Serv. Res."},{"issue":"6","key":"e_1_3_5_25_2","first-page":"469","article-title":"Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population","volume":"8","author":"Ollendorf DA","year":"2002","unstructured":"Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J. Manag. Care Pharm. 8(6), 469\u2013476 (2002).","journal-title":"J. Manag. Care Pharm."},{"issue":"4","key":"e_1_3_5_26_2","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3111\/13696998.2010.523670","article-title":"Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims","volume":"13","author":"Chastek BJ","year":"2010","unstructured":"Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J. Med. Econ. 13(4), 618\u2013625 (2010).","journal-title":"J. Med. Econ."},{"key":"e_1_3_5_27_2","unstructured":"U.S. Bureau of Labor Statistics. CPI Medical care services (2013\u20132020)(2021). www.bls.gov\/cpi\/data.html"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","first-page":"102162","DOI":"10.1016\/j.msard.2020.102162","article-title":"A literature review of cost-of-illness studies on the economic burden of multiple sclerosis","volume":"43","author":"Paz-Zulueta M","year":"2020","unstructured":"Paz-Zulueta M, Par\u00e1s-Bravo P, Cantarero-Prieto D, Bl\u00e1zquez-Fern\u00e1ndez C, Oterino-Dur\u00e1n A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult. Scler. Relat. Disord. 43, 102162 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"e_1_3_5_29_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40801-021-00251-w","article-title":"Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy","volume":"8","author":"Freeman L","year":"2021","unstructured":"Freeman L, Kee A, Tian M, Mehta R. Retrospective claims analysis of treatment patterns, relapse, utilization, and cost among patients with multiple sclerosis initiating second-line disease-modifying therapy. Drugs Real World Outcomes 8(4), 497\u2013508 (2021).","journal-title":"Drugs Real World Outcomes"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.msard.2020.102717","article-title":"Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8 years","volume":"49","author":"Bass AD","year":"2021","unstructured":"Bass AD, Arroyo R, Boster AL ; Care-Ms I C-MI, CAMMS03409, and TOPAZ Investigators. Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8 years. Mult. Scler. Relat. Disord. 49, 102717 (2021).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"9","key":"e_1_3_5_31_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/jnnp-2020-325304","article-title":"Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab","volume":"92","author":"Pfeuffer S","year":"2021","unstructured":"Pfeuffer S, Ruck T, Pul R Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. J. Neurol. Neurosurg. Psychiatry 92(9), 1007\u20131013 (2021).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"e_1_3_5_32_2","doi-asserted-by":"crossref","first-page":"175628641982654","DOI":"10.1177\/1756286419826547","article-title":"Evolution of clinical trials in multiple sclerosis","volume":"12","author":"Zhang Y","year":"2019","unstructured":"Zhang Y, Salter A, Wallstr\u00f6m E, Cutter G, St\u00fcve O. Evolution of clinical trials in multiple sclerosis. Ther. Adv. Neurol. Disord. 12, 1756286419826547 (2019).","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"14","key":"e_1_3_5_33_2","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1212\/WNL.0000000000003169","article-title":"Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \u03b2-1a in MS","volume":"87","author":"Arnold DL","year":"2016","unstructured":"Arnold DL, Fisher E, Brinar VV Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon \u03b2-1a in MS. Neurology 87(14), 1464\u20131472 (2016).","journal-title":"Neurology"},{"issue":"11","key":"e_1_3_5_34_2","first-page":"CD010968","article-title":"Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis","volume":"11","author":"Zhang J","year":"2017","unstructured":"Zhang J, Shi S, Zhang Y Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis. Cochrane Database Syst. Rev. 11(11), CD010968 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"e_1_3_5_35_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/CEOR.S55779","article-title":"Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US","volume":"6","author":"Bonafede MM","year":"2013","unstructured":"Bonafede MM, Johnson BH, Watson C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon. Outcomes Res. 6, 11\u201320 (2013).","journal-title":"Clinicoecon. Outcomes Res."},{"issue":"1","key":"e_1_3_5_36_2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s41669-017-0035-2","article-title":"Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data","volume":"2","author":"Nicholas J","year":"2018","unstructured":"Nicholas J, Boster A, Wu N Comparison of disease-modifying therapies for the management of multiple sclerosis: analysis of healthcare resource utilization and relapse rates from US insurance claims data. Pharmacoecon. Open 2(1), 31\u201341 (2018).","journal-title":"Pharmacoecon. Open"},{"issue":"1","key":"e_1_3_5_37_2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s12325-020-01570-0","article-title":"Annual cost burden by level of relapse severity in patients with multiple sclerosis","volume":"38","author":"Nicholas J","year":"2021","unstructured":"Nicholas J, Zhou H, Deshpande C. Annual cost burden by level of relapse severity in patients with multiple sclerosis. Adv. Ther. 38(1), 758\u2013771 (2021).","journal-title":"Adv. Ther."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2022-0127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:41:58Z","timestamp":1679229718000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2217\/cer-2022-0127"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0127","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"cer-2022-0127"}}